New drug cocktail targets rare liver cancer in 29-Patient trial
Disease control
Not yet recruiting
This study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus chemotherapy (gemcitabine and cisplatin) in people with a rare, advanced liver cancer called combined hepatocellular-cholangiocarcinoma that cannot be removed by surgery or has spread. Ab…
Phase: PHASE2 • Sponsor: Mehmet Akce • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC